Malignant Mixed Neoplasm — Trials

Malignant Mixed Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

348 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 96
Recruiting: 48
Ph III recruiting: 12
Growth YoY: —
Industry share: 7%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (43)

clinicaltrialsPublishedShowing 51–100 of 105 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04195555	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)	active not recruiting	Phase 2	3	National Cancer Institute (NCI)NIH	3	Jul 1, 2026	clinicaltrials
NCT06625190	Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors	recruiting	Phase 1 / Phase 2	27	University of FloridaOTHER	1	Jun 30, 2026	clinicaltrials